MCL Literature Feed

This review explains MCL's clinical heterogeneity through distinct molecular subtypes and genomic alterations like TP53, which serve as key prognostic biomarkers and guide development of novel therapies.

Analysis of the FIL MCL0208 trial shows that stem cell collection and subsequent hematological recovery are feasible and safe in young, fit MCL patients undergoing frontline autologous transplant consolidation.

For transplant-eligible MCL, substituting rituximab with obinutuzumab in chemo-immunotherapy induction and maintenance significantly improved MRD negativity, 5-year progression-free survival (83% vs 67%), and overall survival.

This commentary evaluates rituximab's evolving role in MCL, questioning its necessity in modern chemo-free regimens and its place alongside novel targeted agents.

This case report describes a rare presentation of MCL with paraneoplastic membranous nephropathy, highlighting the need to consider MCL in the differential diagnosis of unexplained nephrotic syndrome.

This multicenter retrospective study analyzes real-world maintenance strategies in mantle cell lymphoma, providing evidence to guide treatment selection and duration after initial therapy.

Preclinical data show WEE1 inhibition synergizes with bortezomib by inducing mitotic pyroptosis, a novel cell death mechanism, suggesting a potential strategy to overcome proteasome inhibitor resistance in MCL.

This study of Burkitt Lymphoma reveals the key MCL oncogene SOX11 has a context-dependent function, with a transcriptional program and downstream effects differing from its established role in MCL.

This paper identifies a subset of MCL with IRTA1-positive reactive marginal zone expansion, highlighting a potential diagnostic pitfall for pathologists distinguishing it from marginal zone lymphoma.

This multicenter real-world study demonstrates that CAR-T therapy can be an effective treatment for MCL patients with secondary CNS involvement, a population with historically poor outcomes.

Preclinical data show combining a BCL-XL inhibitor with venetoclax overcomes resistance in MCL models, even in BIM-deficient cells, suggesting a new strategy for venetoclax-refractory patients.

This review highlights BTK's non-catalytic scaffolding function as a novel mechanism of BTKi resistance, presenting a new therapeutic target beyond kinase inhibition for treating B-cell lymphomas like MCL.

BTK inhibition suppresses key metabolic pathways, allowing non-invasive imaging of metabolites like lactate and alanine as early, sensitive biomarkers of therapeutic response in MCL patients.

A computational, network-based analysis of MCL transcriptomic data identified novel progression pathways, highlighting VEGFA and SPARC as potential drug targets and providing a framework for drug repurposing.

This case report describes a novel nodular endoscopic presentation of primary nasopharyngeal MCL, expanding the differential diagnosis for nodular lesions in this rare location beyond benign or infectious causes.

This case report of an 80-year-old woman with laryngeal MCL highlights a rare extranodal presentation, underscoring the need to consider lymphoma in the differential for persistent throat symptoms.

CD20-targeted CAR-T therapy induced durable remissions (>7 years) in MCL by triggering a lasting endogenous anti-tumor immune response (epitope spreading) despite a lack of CAR-T persistence.

This paper likely provides a retrospective or real-world analysis of the incidence, types, and risk factors for infections in MCL, informing clinical decisions on prophylaxis and supportive care.

A computational virtual screen of over 2.4 million compounds identified novel covalent BTK inhibitors, providing a foundation for developing next-generation therapeutics for MCL.

This large US prospective cohort study suggests outdoor air pollution is a potential environmental risk factor for developing specific hematologic cancer subtypes, highlighting the importance of subtype-specific etiological research.

This case series on a rare kidney disease (ABBA) reports a paraneoplastic association with mantle cell lymphoma, highlighting a rare non-hematologic manifestation potentially responsive to B-cell directed therapy.

This large Chinese retrospective study of blastoid/pleomorphic MCL links progression of disease within 12 months (POD12) to a distinct mutation profile (TP53, SMARCA4) and poor prognosis.

The dual HCK/BTK inhibitor KIN-8194 preclinically overcomes primary and acquired BTKi resistance in MCL by targeting HCK-mediated growth and adhesion, offering a novel therapeutic strategy.

The R-GEMOX (rituximab, gemcitabine, oxaliplatin) chemotherapy regimen demonstrates efficacy as a salvage option for patients with relapsed/refractory mantle cell lymphoma in a phase I/II study.

Bendamustine is a feasible alternative lymphodepletion for brexu-cel in MCL, showing comparable efficacy to standard cy/flu with less cytopenia, providing a critical option during drug shortages.

This review synthesizes current knowledge on MCL genetic markers, advocating for a personalized medicine approach that integrates molecular profiles like TP53 to improve risk stratification and guide therapy.

This preclinical study identifies a novel cyclin D1 degradation pathway via SUMOylation, showing its disruption causes an MCL-like phenotype and that arsenic trioxide can therapeutically enhance this process.

A qualitative study of Japanese MCL patients reveals that convenience, quality of life, and shared decision-making are key treatment preferences, alongside efficacy and safety, guiding personalized care.

In a large real-world cohort, mantle cell lymphoma patients exhibited higher CAR19 expansion than other lymphomas, which directly correlated with increased toxicity and significantly higher steroid requirements.

Profiling T-cell differentiation stages in MCL reveals novel immunotherapeutic targets in specific patient subsets, suggesting a biomarker-driven approach for future immune-based treatments.